Tumor markers of urinary tract carcinoma

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The tumor markers for malignant tumors arisen from urinary system including prostate cancer were reviewed. As for renal cell carcinoma there was no good marker used in routine test level at present. In the diagnosis of urothelial (transitional cell) carcinoma, mainly bladder cancer, 3 methods (urinary BTA, NMP22 and BFP) are used now in Japan. They all seem to be not fully sufficient in respect of the specificity. In foreign countries, new tests such as urinary telomerase and BLCA-4 are used and have been evaluated. On the diagnosis of prostate cancer, serum total PSA is well established and used. Various PSA relation markers have been advocated for the differentiation between benign prostate hypertrophy and carcinoma in so called "gray zone" level of total PSA. In methods based on the molecular forms of PSA, the ratio of free PSA to total PSA (f/T) is widely use, and proPSA is a test that is expected. Other approaches such as volume of index PSA, age specific PSA reference range and PSA velocity are also in practical application. Human glandular kallikrein 2, which belong to the human kallikrein family as well as PSA, is expected as a tumor specific marker.

Original languageEnglish
Pages (from-to)371-380
Number of pages10
JournalRinsho byori. The Japanese journal of clinical pathology
Volume52
Issue number4
Publication statusPublished - 2004

Fingerprint

Tumor Biomarkers
Urinary Tract
Prostatic Neoplasms
Carcinoma
Tissue Kallikreins
Kallikreins
Transitional Cell Carcinoma
Telomerase
Renal Cell Carcinoma
Urinary Bladder Neoplasms
Hypertrophy
Prostate
Japan
Reference Values
Serum
Neoplasms
nuclear matrix protein 22
2-benzyl-3-formylpropanoic acid

Cite this

Tumor markers of urinary tract carcinoma. / Kikuchi, Haruhito.

In: Rinsho byori. The Japanese journal of clinical pathology, Vol. 52, No. 4, 2004, p. 371-380.

Research output: Contribution to journalArticle

@article{a15ff9bbfab04ae5ad7c9c123d61b40e,
title = "Tumor markers of urinary tract carcinoma",
abstract = "The tumor markers for malignant tumors arisen from urinary system including prostate cancer were reviewed. As for renal cell carcinoma there was no good marker used in routine test level at present. In the diagnosis of urothelial (transitional cell) carcinoma, mainly bladder cancer, 3 methods (urinary BTA, NMP22 and BFP) are used now in Japan. They all seem to be not fully sufficient in respect of the specificity. In foreign countries, new tests such as urinary telomerase and BLCA-4 are used and have been evaluated. On the diagnosis of prostate cancer, serum total PSA is well established and used. Various PSA relation markers have been advocated for the differentiation between benign prostate hypertrophy and carcinoma in so called {"}gray zone{"} level of total PSA. In methods based on the molecular forms of PSA, the ratio of free PSA to total PSA (f/T) is widely use, and proPSA is a test that is expected. Other approaches such as volume of index PSA, age specific PSA reference range and PSA velocity are also in practical application. Human glandular kallikrein 2, which belong to the human kallikrein family as well as PSA, is expected as a tumor specific marker.",
author = "Haruhito Kikuchi",
year = "2004",
language = "English",
volume = "52",
pages = "371--380",
journal = "Rinsho byori. The Japanese journal of clinical pathology",
issn = "0047-1860",
publisher = "Nihon Rinsho Byori Gakkai",
number = "4",

}

TY - JOUR

T1 - Tumor markers of urinary tract carcinoma

AU - Kikuchi, Haruhito

PY - 2004

Y1 - 2004

N2 - The tumor markers for malignant tumors arisen from urinary system including prostate cancer were reviewed. As for renal cell carcinoma there was no good marker used in routine test level at present. In the diagnosis of urothelial (transitional cell) carcinoma, mainly bladder cancer, 3 methods (urinary BTA, NMP22 and BFP) are used now in Japan. They all seem to be not fully sufficient in respect of the specificity. In foreign countries, new tests such as urinary telomerase and BLCA-4 are used and have been evaluated. On the diagnosis of prostate cancer, serum total PSA is well established and used. Various PSA relation markers have been advocated for the differentiation between benign prostate hypertrophy and carcinoma in so called "gray zone" level of total PSA. In methods based on the molecular forms of PSA, the ratio of free PSA to total PSA (f/T) is widely use, and proPSA is a test that is expected. Other approaches such as volume of index PSA, age specific PSA reference range and PSA velocity are also in practical application. Human glandular kallikrein 2, which belong to the human kallikrein family as well as PSA, is expected as a tumor specific marker.

AB - The tumor markers for malignant tumors arisen from urinary system including prostate cancer were reviewed. As for renal cell carcinoma there was no good marker used in routine test level at present. In the diagnosis of urothelial (transitional cell) carcinoma, mainly bladder cancer, 3 methods (urinary BTA, NMP22 and BFP) are used now in Japan. They all seem to be not fully sufficient in respect of the specificity. In foreign countries, new tests such as urinary telomerase and BLCA-4 are used and have been evaluated. On the diagnosis of prostate cancer, serum total PSA is well established and used. Various PSA relation markers have been advocated for the differentiation between benign prostate hypertrophy and carcinoma in so called "gray zone" level of total PSA. In methods based on the molecular forms of PSA, the ratio of free PSA to total PSA (f/T) is widely use, and proPSA is a test that is expected. Other approaches such as volume of index PSA, age specific PSA reference range and PSA velocity are also in practical application. Human glandular kallikrein 2, which belong to the human kallikrein family as well as PSA, is expected as a tumor specific marker.

UR - http://www.scopus.com/inward/record.url?scp=3142726153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142726153&partnerID=8YFLogxK

M3 - Article

VL - 52

SP - 371

EP - 380

JO - Rinsho byori. The Japanese journal of clinical pathology

JF - Rinsho byori. The Japanese journal of clinical pathology

SN - 0047-1860

IS - 4

ER -